All-In-One Knowledge Hub

.While Biogen’s pharma peers are actually looking for late-stage possessions along with little bit of danger, CEO Chris Viehbacher intends to generate even more early-stage

.Biogen has handed back rights to an early Alzheimer’s ailment system to Denali Therapies, leaving a big hole in the biotech’s collaboration revenue stream.Biogen has

.Biogen has administered the final ceremonies to its own collaboration with Sage Therapeutics on SAGE-324, breaking up the collaboration in the results of an unsuccessful

.Biogen and also UCB’s gamble on improving right into phase 3 on the back of a broken research tries to have paid, along with the

.Welcome to recently’s Chutes &amp Ladders, our roundup of notable leadership hirings, shootings as well as retirings throughout the business. Please send the good word–

.After BioMarin carried out a spring clean of its pipe in April, the company has decided that it additionally needs to unload a preclinical genetics

.BioMarin is adding combustion to the R&ampD fire, assaulting a suit along with CAMP4 Therapies for rights to pick pair of targets determined due to

.Welcome to this week’s Chutes &amp Ladders, our summary of significant leadership hirings, firings and also retirings throughout the field. Please send the praise– or

.BioAge Labs is actually bringing in nearly $200 thousand through its Nasdaq IPO this morning, along with the profits set aside for taking its own

.BioAge Labs is checking out around $180 million in preliminary earnings from an IPO and also a personal positioning, funds the metabolic-focused biotech will make